At the last check on Friday, Amgen Inc.’s (NASDAQ:AMGN) stock was down -$1.09, moving down -0.41 percent to $262.76. The average number of shares traded per day over the past five days has been 2,046,378 shares. 3 times new highs have been achieved over the past 5 days, with a $0.19 gain in that time frame. In the last twenty days, the average volume was 2,465,465, while in the previous 50 days, it was 2,651,444.
Since last month, AMGN stock rose 12.66%. Shares of the company fell to $228.21 on 08/03/23, the lowest level in the past month. A 52-week high of $296.67 was reached on 01/11/23 after having rallying from a 52-week low of $211.71. Since the beginning of this year, AMGN’s stock price has risen by 0.05% or $0.06, and marked a new high 5 times. However, the stock has declined by -11.43% since its 52-week high.
AMGN stock investors should be aware that Amgen Inc. (AMGN) stock had its last reported insider trading activity 8 days ago on Aug 10. Gordon Murdo, the EVP, Global Commercial Ops of the company, disposed of 9,558 shares for $262.43 on Aug 10. It resulted in a $2,508,306 divestment by the insider. Khosla Rachna sold 387 shares at an average price of $292.90 on Nov 09. The insider now owns 6,630 shares following the transaction. On Nov 08, SVP & CCO Grygiel Nancy A. sold 545 shares at $293.54 apiece. The transaction was valued at $159,977.
Valuation Metrics
Right now, Amgen Inc. (AMGN) has a P/E ratio of about 17.71. The stock’s beta is 0.58. Besides these, the trailing price-to-sales (P/S) ratio of 5.28, the price-to-book (PB) ratio of 20.74, and the price-to-cash flow ratio of 14.49 may also be considered.
The latest dividend of $2.13 per share was paid out, remained unchanged from last year’s $2.13. On Monday December 12 2022, a $0.19 dividend increase was announced.
Financial Health
In the three months ended June 29, Amgen Inc.’s quick ratio stood at 2.50, while its current ratio was 2.80, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 8.76, and the total debt-to-equity ratio was 9.08. On the profitability front, the trailing twelve-month gross margin is 74.50% percent. In the year ended June 29, EBITDA margin amounted to 48.28%, whereas operating margins totaled 36.40%. Based on annual data, AMGN earned $19.92 billion in gross profit and brought in $26.32 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 20.80%. Return on equity (ROE) for the past 12 months was 164.20%.
In Amgen Inc.’s quarter-end financial report for June 29, it reported total debt of $59.38 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. AMGN’s revenue rose 5.61% to $6.11 billion during the quarter, while net income inched up to $6.99 billion. While analysts expected Amgen Inc. to report $4.13 quarterly earnings, the actual figure was $4.6 per share, beating the consensus estimate by 11.40%. During the quarter, the company generated $3.58 billion in EBITDA. The liabilities of Amgen Inc. were 83.49 billion at the end of its most recent quarter ended June 29, and its total debt was $61.54 billion. The value of shareholders’ equity is $534.9 million.
Technical Picture
This quick technical analysis looks at Amgen Inc.’s (AMGN) price momentum. With a historical volatility rate of 19.32%, the RSI 9-day stood at 72.74% on 17 August.
With respect to its five-day moving average, the current Amgen Inc. price is up by +0.07% percent or $0.19. At present, AMGN shares trade +11.87% above its 20-day simple moving average and +10.96% percent above its 100-day simple moving average. However, the stock is currently trading approximately +18.73% above its SMA50 and -2.83% below its SMA200.
Stochastic coefficient K was 89.05% and Stochastic coefficient D was 91.83%, while ATR was 4.91. Given the Stochastic reading of 86.16% for the 14-day period, the RSI (14) reading has been calculated as 73.05%. As of today, the MACD Oscillator reading stands at 1.27, while the 14-day reading stands at 10.09.
Analyst Ratings
Oppenheimer reiterated its an Outperform rating on Amgen Inc. (NASDAQ: AMGN) in a note to investors. The analysts firm has however raised their price target to $290, representing a possible 10.01% increase in the stock price. Amgen Inc. (AMGN) has been rated Hold by analysts. According to 3 brokerage firms, AMGN is a sell, and 13 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate Amgen Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $260.00, the current consensus forecast for the stock is $175.00 – $310.00. Based on these forecasts, analysts predict Amgen Inc. (AMGN) will achieve an average price target of $252.94.
